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Introduction
Lipid emulsions are an important part of paediatric parenteral 
nutrition as they provide energy, fat soluble vitamins and are a 
source of essential fatty acids. Soya bean based oil emulsions 
have however been identified as one of the major causative factors 
in the development of PN related cholestasis. The newer lipid 
emulsion containing fish oil has been shown to reduce the risk 
of such complications. Nevertheless, some centers advise that 
parenteral lipid intake should be discontinued when parenteral 
nutrition associated cholestasis (PNAC) develops. This practice is, 
however, not recommended as it can be detrimental to infants who 
have limited fat stores. Such practices, could also potentially lead to 
growth failure and essential fatty acid deficiency. Increasing daily 
intravenous glucose intake as a compensatory measure for the 
omission of lipid emulsions is not recommended as it may induce 
insulin resistance and the risk of liver steatosis due to lipogenesis.1,2
Prolonged parenteral nutrition (PPN) is essential in those paediatric 
patients who are unable to meet their full dietary requirements via 
the enteral route. Many of these patients are dependant on parenteral 
nutrition (PN) for growth, development and survival. Lipid emulsions 
form an important part of parenteral nutrition as a non- carbohydrate 
source of energy and supplies both essential fatty acids and lipid-
soluble vitamins.3
Long-term PN is related to various serious complications with 
PN associated liver disease having been identified as one of the 
most serious complications as it may progress to cirrhosis and 
liver failure.4,5 The prevalence of parenteral nutrition associated 
cholestasis (PNAC) has been reported to be more frequent and 
severe in infants than in adults with a 30-70% prevalence of 
hepatic dysfunction seen in infants.5,6 Children with PNAC also 
predominantly present with a cholestatic picture. Hepatic immaturity 
has been identified as a major predisposing factor with an increased 
prevalence seen in premature, very low birth weight and small 
for gestational age infants. Treatment options are limited and is 
associated with a relatively high mortality.2
The etiology of PNAC is multi-factorial and risk factors for its 
development include sepsis, e.g. catheter infections or necrotizing 
enterocolitis, bacterial overgrowth, impaired bile acid recirculation 
as seen in short bowel syndrome, multiple operative procedures, 
delayed enteral feeding, prolonged parenteral nutrition, overfeeding 
via parenteral nutrition and IV lipid emulsions.2,5-7
When a patient develops PNAC it is important that all possible 
contributing factors are identified and addressed. The early 
introduction of Enteral Nutrition (EN) may slow the progression of 
PNAC and cholestasis may be reversed once PN is discontinued. 
This may however prove challenging especially in the presence of 
poor EN tolerance due to intestinal dysfunction. 2 Other management 
strategies include preventing and/or treating bacterial overgrowth, 
pharmacotherapy, and considering modifications to the PN solution.5
The use of soya bean oil based lipid emulsions
Soya bean oil has been the standard lipid emulsion used in parenteral 
nutrition for many years due to the lack of alternative options. 
It is composed of long chain triglycerides and contains > 60% 
polyunsaturated fatty acids (PUFA). It also acts as a reliable source 
of essential fatty acids with an omega 6:omega 3 ratio of 5.5:1.8 
Soya bean oil has been implicated in PNAC with clinical observations 
showing a dose related relationship in the development of PNAC. 
The potential causative factors identified include enhanced oxidative 
stress, prolonged inflammation and the role of phytosterols.7,8
Oxidative stress
Lipid metabolism results in lipid peroxidation and free radical 
formation.3 Reactive oxygen species cause functional damage to 
hepatocytes and lead to reduced bile production and cholestasis in 
animal models. Soya is a relatively poor source of alpha-tocopherol, 
which, if not supplemented, may lead to reduced levels in plasma 
lipoproteins and depletion of anti-oxidant defenses during long-term 
PN usage.6 There appears to be an enhancement of lipid peroxidation 
when the supply of parenteral polyunsaturated fatty acids is 
increased in the presence of a low supply of alpha tocopherol.1
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The increased risk of lipid peroxidation is of particular concern in 
premature infants who are known to be exposed to oxidative stress 
and are more vulnerable to its effects when compared to neonates.9,10 
This patient population is also prone to being dependant on PN while 
enteral intake is being established.
Prolonged inflammation
Prolonged inflammation is a component of PNAC that contributes 
to progressive liver damage, cholestasis and fibrosis. Soya bean 
emulsions provide large amounts of linoleic acid which can be 
converted to arachidonic acid (AA), a pre-cursor of potent pro-
inflammatory mediators.6
Phytosterols
Recent studies suggest that phytosterols contribute to cholestasis due 
to their effect on biliary secretion.2 Phytosterols are not metabolized 
efficiently by the liver.5 Regular use of phytosterols in animal models 
have shown to lead to reduced bile flow and increased bile acid 
levels. Accumulation of phytosterols has also been seen in blood 
samples of children with PNAC.6
There have been reports of unfavorable changes in lipid profiles in 
patients on soya based PN. These include hypertriglyceridaemia, 
hypercholesterolaemia, decreased HDL and increased LDL con- 
centrations.4
Fish oil based lipid emulsions
The use of fish oil has been proposed as a possible alternative 
option to soya bean as a lipid emulsion especially in treating and/
or preventing PNAC. The addition of fish oil leads to the reduction 
in some of the adverse effects of soya and the provision of the 
beneficial effects of fish oil. 
The addition of fish oil achieves a reduction in omega 6 fatty acids and 
a higher intake of omega 3 fatty acids. Long chain polyunsaturated 
fatty acids, especially omega 3 fatty acids from fish oil, possess the 
most potent immunomodulatory and anti-inflammatory properties.3 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from 
fish oil have anti-inflammatory properties and may be beneficial 
in hyper inflammatory settings. They are however susceptible to 
peroxidation especially during inadequate antioxidant availability.6,11 
Fish oil based emulsions also contain no phytosterols. This 
composition allows for the improvement of anti oxidant defenses 
and the suppression of the adverse effects of phytosterols.8 Recent 
studies have suggested that fish oil based emulsions may lead to 
faster reversal of cholestasis when replacing standard soya bean 
oil. Gura et al have reported a median time of 9.4 weeks to reversal 
of cholestasis vs. 44.1 weeks when compared to a control group 
receiving soya bean oil. The authors also documented a 4.8 times 
faster reversal of cholestasis in the treatment group.6
A double blind randomized controlled trial assessed the effect of 
fish oil omega 3 fatty acids on oxidative stress in preterm infants. 
The authors found a decrease in oxidative stress and an increase 
in vitamin E levels when compared to a standard lipid emulsion.9 
Furthermore, Le et al observed an improvement in the lipid profiles 
of patients receiving a fish oil based emulsion. Positive changes 
seen included a decrease in LDL, VLDL, cholesterol and triglyceride 
concentrations and an upward trend in HDL levels.4 These changes 
may be due to the ability of omega 3 fatty acids to reduce the 
hepatic triglycerides synthesis,2,4 a reduction which could reduce 
inflammation in the liver.4
Mixed lipid emulsions
Long-term use of fish oil as the sole lipid source provides lesser 
amounts of essential fatty acids than those needed in infants and 
young children. Both omega 6 and omega 3 fatty acids have been 
shown to be essential for growth and development.7 In this regard, 
available evidence indicates that the sole use of fish oil based 
emulsions is not essential and that the same beneficial effects on the 
liver may be derived by combining fish oil with other lipid emulsions 
with the addition of alpha tocopherol.7
SMOFlipid 20% (Fresenius Kabi) is a new lipid emulsion that contains 
a mixture of 30% soya bean oil, 30% medium chain triglycerides 
(MCT), 25% olive oil and 15% fish oil. It contains added alpha 
tocopherol (200 mg/liter) and provides an omega 6:omega 3 ratio 
of 2.5:1.This ratio is within the optimal range to provide an anti-
inflammatory effect and correlates with the composition of breast 
milk.8,10
Medium chain triglycerides are sourced from coconut or palm kernel 
oil and acts as a rapidly available energy source. They are eliminated 
faster from the bloodstream than long chain triglycerides and do 
not depend on carnitine for mitochondrial transport. MCTs are less 
susceptible to lipid peroxidation and do not accumulate in the liver. 
MCTs are also widely used in infants and neonates and have been 
shown to be safe for long term administration.6,10    
Olive oil is rich in monounsaturated fatty acids thereby reducing 
excessive polyunsaturated fatty acid use. Olive oil lipid emulsions 
have also been shown to be safe in the use of premature infants and 
older children. Olive oil emulsions though do not provide sufficient 
omega 3 fatty acids.10 A study evaluating the effects of soybean oil 
vs. an olive oil and soybean oil emulsion on peroxidation and plasma 
phospholipids fatty acids in premature infants found a better vitamin 
E status and a fatty acid composition more similar to breastfed 
infants in the olive oil group.1
Evidence from controlled trials have shown that by even including 
part of the lipid emulsion as fish oil can provide similar beneficial 
effects. By increasing the ratio of omega 3: omega 6, the metabolism 
of AA is reduced, which is thought to be associated with a reduced 
production of the pro-inflammatory cytokines implicated in PNAC.10 
Soya bean oil was included in the lipid emulsion as it is a reliable 
source of essential fatty acids in the form of linoleic acid and alpha 
linoleic acid. This is particularly important since the risk of essential 
fatty acid deficiency is high in the infant population and clinical signs 
of deficiency have been reported in situations where fat free TPN 
has been used.1
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A double blind randomized controlled trial conducted in 28 paediatric 
patients (ages five months-11 years) on home PN evaluated the 
safety, tolerability and efficacy of SMOF lipid over a 4 week period at 
a dose of 1g/kg IV lipid/day. The authors found a positive influence on 
serum alpha tocopherol levels and omega 3 fatty acid status without 
changing lipid peroxidation parameters. A significant decrease 
was also seen in bilirubin levels as well as an improvement in liver 
function tests. This lipid emulsion was well tolerated.10 Similarly, 
such beneficial effects were also reported in 51 premature infants 
on PN who were randomized to receive either SMOF lipid PN or 
conventional soya based PN. The infants received an average lipid 
intake of 1.6 g/kg/day. The changes observed were an increase in 
alpha tocopherol, decrease in gamma-glutamyl transpeptidase (GGT) 
levels and an increase in the availability of omega 3 fatty acids. The 
increased availability of the omega 3 fatty acids is seen as beneficial 
for this patient population as DHA accumulation is most active in the 
last intrauterine trimester.11
The new lipid emulsions used in recent trials were well tolerated 
and the mean triglyceride levels were well below critical levels 
being 0.62 mmol/l at baseline for both groups and remaining at 
0.87 mmol/l and 0.82 mmol/l at termination of the study. The 
monitoring of triglyceride levels is seen as the primary safety variable 
during the administration of PN. Premature neonates are at higher 
risk of hypertrygliceridaemia due to their limited muscle and fat 
mass and subsequent decreased hydrolytic capacity of lipoprotein 
lipase.11 These positive effects may serve to protect premature 
infants from increased levels of oxidative stress and benefit their 
cognitive development and visual capacity.11
It is of utmost importance that treatment strategies for the 
prevention of PNAC is incorporated into the management plan of 
all patient who are receiving long term parenteral nutrition. The 
use of a multi-lipid emulsion is advised as one of the preventative 
and/or treatment strategies as it has been identified as a safe and 
well tolerated vehicle to combine the beneficial aspects of different 
lipid emulsions in both the prevention and treatment of parenteral 
nutrition associated liver disease. 
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